Department of Medicine, University of California, San Francisco, California.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Cancer Discov. 2019 May;9(5):587-604. doi: 10.1158/2159-8290.CD-18-1196. Epub 2019 Apr 16.
With advances in technology and bioinformatics, we are now positioned to view and manage cancer through an evolutionary lens. This perspective is critical as our appreciation for the role of tumor heterogeneity, tumor immune compartment, and tumor microenvironment on cancer pathogenesis and evolution grows. Here, we explore recent knowledge on the evolutionary basis of cancer pathogenesis and progression, viewing tumors as multilineage, multicomponent organisms whose growth is regulated by subcomponent fitness relationships. We propose reconsidering some current tenets of the cancer management paradigm in order to take better advantage of crucial fitness relationships to improve outcomes of patients with cancer. SIGNIFICANCE: Tumor and tumor immune compartment and microenvironment heterogeneity, and their evolution, are critical disease features that affect treatment response. The impact and interplay of these components during treatment are viable targets to improve clinical response. In this article, we consider how tumor cells, the tumor immune compartment and microenvironment, and epigenetic factors interact and also evolve during treatment. We evaluate the convergence of these factors and suggest innovative treatment concepts that leverage evolutionary relationships to limit tumor growth and drug resistance.
随着技术和生物信息学的进步,我们现在能够从进化的角度来观察和管理癌症。这种观点至关重要,因为我们越来越认识到肿瘤异质性、肿瘤免疫区室和肿瘤微环境在癌症发病机制和进化中的作用。在这里,我们探讨了癌症发病机制和进展的进化基础的最新知识,将肿瘤视为多谱系、多成分的生物体,其生长受亚成分适应性关系的调节。我们建议重新考虑癌症管理范式的一些当前原则,以便更好地利用关键的适应性关系,改善癌症患者的治疗效果。意义:肿瘤和肿瘤免疫区室和微环境的异质性及其进化是影响治疗反应的关键疾病特征。在治疗过程中,这些成分的影响和相互作用是提高临床反应的可行目标。在本文中,我们考虑了肿瘤细胞、肿瘤免疫区室和微环境以及表观遗传因素在治疗过程中如何相互作用和进化。我们评估了这些因素的收敛性,并提出了利用进化关系来限制肿瘤生长和耐药性的创新治疗概念。